Cargando…

Patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in China

BACKGROUND: Poor adherence to treatment is a problem in glaucoma, and patient dissatisfaction with topical glaucoma medication is a barrier to adherence. The objective of this study was to evaluate glaucoma patients’ satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution (BTFC)....

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xinghuai, Lin, Mingkai, Duan, Xuanchu, Zhang, Chun, Ming, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417666/
https://www.ncbi.nlm.nih.gov/pubmed/28496310
http://dx.doi.org/10.2147/PPA.S131853
_version_ 1783233931691163648
author Sun, Xinghuai
Lin, Mingkai
Duan, Xuanchu
Zhang, Chun
Ming, Jian
author_facet Sun, Xinghuai
Lin, Mingkai
Duan, Xuanchu
Zhang, Chun
Ming, Jian
author_sort Sun, Xinghuai
collection PubMed
description BACKGROUND: Poor adherence to treatment is a problem in glaucoma, and patient dissatisfaction with topical glaucoma medication is a barrier to adherence. The objective of this study was to evaluate glaucoma patients’ satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution (BTFC). METHODS: This observational, multicenter study was conducted in China in adults with glaucoma treated with BTFC for 1–3 months. Five hundred patients answered a questionnaire concerning their demographic characteristics, history of glaucoma and topical glaucoma treatment, and use of BTFC. The primary endpoint was patient satisfaction with BTFC assessed on a 10-point scale (1= very dissatisfied, 10= very satisfied). RESULTS: Patients received BTFC alone (65%) or with other treatments (35%), most commonly a carbonic anhydrase inhibitor. Most patients (87%) used BTFC as a replacement for other medication, usually a β-blocker or prostaglandin analog; 13% received BTFC as add-on treatment. Key reasons for initiating BTFC therapy were poor efficacy of previous treatment (72% of patients) and side effects of previous treatment (32% of patients). Most patients agreed or very much agreed that BTFC provided better control of intraocular pressure (85% of patients), had a simpler administration (87% of patients), and was associated with better tolerance and comfort (82% of patients) compared with their previous treatment. Mean satisfaction scores were significantly higher for BTFC than for previous treatments among all patients (7.8 versus 6.0; P<0.0001) and within patient subgroups based on demographic characteristics, pattern of BTFC use, and previous treatment. CONCLUSION: Patients were highly satisfied with BTFC used alone or concomitantly with another topical medication. Patients previously treated with a β-blocker, prostaglandin analog, carbonic anhydrase inhibitor, α-adrenergic agonist, or combination of two medications were more satisfied with BTFC than with their previous treatment. Most reported that intraocular pressure control, tolerability, and ease of administration improved with BTFC.
format Online
Article
Text
id pubmed-5417666
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54176662017-05-11 Patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in China Sun, Xinghuai Lin, Mingkai Duan, Xuanchu Zhang, Chun Ming, Jian Patient Prefer Adherence Original Research BACKGROUND: Poor adherence to treatment is a problem in glaucoma, and patient dissatisfaction with topical glaucoma medication is a barrier to adherence. The objective of this study was to evaluate glaucoma patients’ satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution (BTFC). METHODS: This observational, multicenter study was conducted in China in adults with glaucoma treated with BTFC for 1–3 months. Five hundred patients answered a questionnaire concerning their demographic characteristics, history of glaucoma and topical glaucoma treatment, and use of BTFC. The primary endpoint was patient satisfaction with BTFC assessed on a 10-point scale (1= very dissatisfied, 10= very satisfied). RESULTS: Patients received BTFC alone (65%) or with other treatments (35%), most commonly a carbonic anhydrase inhibitor. Most patients (87%) used BTFC as a replacement for other medication, usually a β-blocker or prostaglandin analog; 13% received BTFC as add-on treatment. Key reasons for initiating BTFC therapy were poor efficacy of previous treatment (72% of patients) and side effects of previous treatment (32% of patients). Most patients agreed or very much agreed that BTFC provided better control of intraocular pressure (85% of patients), had a simpler administration (87% of patients), and was associated with better tolerance and comfort (82% of patients) compared with their previous treatment. Mean satisfaction scores were significantly higher for BTFC than for previous treatments among all patients (7.8 versus 6.0; P<0.0001) and within patient subgroups based on demographic characteristics, pattern of BTFC use, and previous treatment. CONCLUSION: Patients were highly satisfied with BTFC used alone or concomitantly with another topical medication. Patients previously treated with a β-blocker, prostaglandin analog, carbonic anhydrase inhibitor, α-adrenergic agonist, or combination of two medications were more satisfied with BTFC than with their previous treatment. Most reported that intraocular pressure control, tolerability, and ease of administration improved with BTFC. Dove Medical Press 2017-04-28 /pmc/articles/PMC5417666/ /pubmed/28496310 http://dx.doi.org/10.2147/PPA.S131853 Text en © 2017 Sun et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Sun, Xinghuai
Lin, Mingkai
Duan, Xuanchu
Zhang, Chun
Ming, Jian
Patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in China
title Patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in China
title_full Patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in China
title_fullStr Patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in China
title_full_unstemmed Patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in China
title_short Patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in China
title_sort patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in china
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417666/
https://www.ncbi.nlm.nih.gov/pubmed/28496310
http://dx.doi.org/10.2147/PPA.S131853
work_keys_str_mv AT sunxinghuai patientsatisfactionwithfixedcombinationbimatoprosttimololophthalmicsolutionasurveystudyinpatientswithglaucomainchina
AT linmingkai patientsatisfactionwithfixedcombinationbimatoprosttimololophthalmicsolutionasurveystudyinpatientswithglaucomainchina
AT duanxuanchu patientsatisfactionwithfixedcombinationbimatoprosttimololophthalmicsolutionasurveystudyinpatientswithglaucomainchina
AT zhangchun patientsatisfactionwithfixedcombinationbimatoprosttimololophthalmicsolutionasurveystudyinpatientswithglaucomainchina
AT mingjian patientsatisfactionwithfixedcombinationbimatoprosttimololophthalmicsolutionasurveystudyinpatientswithglaucomainchina